header logo image


Page 706«..1020..705706707708..720730..»

Mobile blast in mouth injure Yemen youth, gets fresh lease of life with facial reconstruction surgery in India – ANI News

February 13th, 2020 12:46 pm

ANI | Updated: Feb 13, 2020 14:53 IST

New Delhi [India], Feb 13 (ANI): A 26-year-old youth from Yemen, Saad-Ul- Haq (name changed) has received a fresh lease of life by getting his normal face back through a rare reconstructive surgery, performed by a team of Indian doctors.A few months back, Saad's face and mouth was left completely disfigured after a mobile blasted in his mouth which he had held between his teeth while doing some work.Apart from severe disfiguring, the accident rendered him incapable to eat and speak normally, said doctors.Team of facial Reconstruction Surgeons headed by Dr Ajaya Kashyap performed a rare surgical procedure to give Saad his normal facial features back.The blast was so strong that it burnt the inside of his mouth, tore up the muscles and the tongue leaving all the soft tissues damaged, said the doctors.Dr Ajaya Kashyap, Medical Director, KAS Medical Centre, New Delhi said "As the blast happened inside the mouth, the injury was rather unusual. After much assessment, the team decided to use flaps of tissue from inside the mouth as well as fat tissues from his body and use it as a flap. Ensuring facial sensations was another challenge. We are happy that the procedure went well and the patient regained his normal features.""The muscles of the lips which had been split apart were repaired and flaps were used to close it. Autologous fat with stem cells and PRP were injected to restore volume and improve scarring. The surgery of Saad was done a week back and now he is ready to fly back to his own country," said Dr Kashyap. Sharing his experience in India, Saad (patient) said, "The blast had taken everything that was positive in me. Unable to eat and speak, just a few months ago I was the most hopeless man. When we started off from Yemen, all I hoped was to get my normal features back. For me, the surgery has changed everything. Now I can get settled in my life and get married to my girl without feeling insecure about my looks." (ANI)

See more here:
Mobile blast in mouth injure Yemen youth, gets fresh lease of life with facial reconstruction surgery in India - ANI News

Read More...

Mammals Can Delay The Development of Their Embryos, According to Recent Research – Dual Dove

February 13th, 2020 12:46 pm

Recent research sheds light on something quite peculiar, exploring a reproductive mystery that is present in more than 130 species of mammals. A team of researchers conducted by Abdiasis Hussein, an associate director of UW Medicines Institute for Stem Cell, also a UW professor of biochemistry, realized the intriguing findings on mammals.

The results not only bring more details for the understanding of postponed embryo implantation. It also indicates how some quickly splitting cells, such as those present in tumors, turn to be inactive.

To find out what leads to a biochemical hold-and-release on embryonic production, the team provoked diapause in a female mouse by decreasing the estrogen rates. Then, they realized a comparison of the diapause embryos to pre-implantation and post-implantation ones. They also provoked diapause in mouse embryonic stem cells by weakening the cells, and analyze those to actively developing mouse embryonic stem cells.

Researchers had also performed comprehensive investigations of how metabolic and signaling pathways manage both the inactive and active phases of mouse embryos and mouse embryonic stem cells in lab vessels.

Metabolism involves the life-supporting chemical actions cells take out to turn substances into energy, develop materials, and discharge waste. By examining those reactions final actions, dubbed metabolites, the researchers could start to realize the full picture of that occurs to cause diapause and how cells are delivered from its grips.

Bears, seals, weasel-like animals, or armadillos, experience seasonal diapause, as a regular part of their reproductive periods. Many classes of bears, for example, breed in the early stages of spring and sometimes even in early summer. The female then uncontrollable hunts for food, and only when it reaches sufficient weight and body fat, one or more of her embryos implant a few months later after she moves to her cave. Any baby bears would be born in late winter.

Ethelene is the main editor on DualDove, she likes to write on the latest science news.

View post:
Mammals Can Delay The Development of Their Embryos, According to Recent Research - Dual Dove

Read More...

How to get rid of visceral fat: Four foods proven to banish the dangerous belly fat – Express

February 13th, 2020 12:46 pm

Visceral fat, as opposed to subcutaneous fat, lies deep inside the body and is a type of fat many leading health experts stress about how dangerous it is due to its proximity to vital organs making it potentially life-threatening. Visceral fat has been linked to metabolic disturbances and increased risk for cardiovascular disease and type 2 diabetes. Fortunately, certain foods help to reduce visceral fat, keep you feeling fuller for longer and not high in calories - here are four such foods.

Research shows that coconut oil doesnt negatively impact blood lipid levels like once believed and it may even help to promote a reduction in stomach fat.

The belly fat-fighting properties of coconut oil stem from the amount of medium chain triglycerides contained which are metabolised quickly and therefor stand less of a chance to be stored as adipose, said Kayleen St. John executive director of Nutrition and Strategic Development of Euphebe.

READ MORE: Stephanie Davis health: The pain took over my mind, body and soul Stars difficult time

"Fructose has (rightly so) gotten a bad reputation lately for its role in promoting central obesity or belly fat," says St.John.

"However, fructose found in whole foods like fruit does not act so sinisterly in the body. Fresh or frozen raspberries contain a great deal of fibre, which helps to regulate the body's insulin response and also reduce belly fat.

"If a fresh pint comes with a steep price tag at your local grocer, consider buying them frozen: they're cost-effective, last practically forever, and are picked at the peak of freshness."

DONT MISS

Research continues to show that enjoying soup before a meal reduces the total caloric load of that meal, which help to banish belly fat, says Julieanna Hever, author of The Vegetarian Diet.

Filling up on high-fibre foods like a low-calorie soup is so satisfying that you end up eating less overall, thereby reducing your visceral fat.

Like onions and leeks, these green vegetables are prebiotic foods that produce acetate, an acid that turns on the fat-burning activity in the cells by helping them recover from inflammation.

A study published in the International Journal of Obesity compared weight loss after an egg breakfast compared to a bagel breakfast containing similar calories, explains Toby Amidor, author of The Greek Yoghurt Kitchen.

Results found that participants who consumed two eggs in their breakfast while following a lower-calorie diet lost 65 percent more weight and reduced their waist circumference by 34 percent compared with those who were on a similar calorie bagel breakfast.

Eggs are also a great source of protein, which works to keep hunger at bay and curb overeating.

Original post:
How to get rid of visceral fat: Four foods proven to banish the dangerous belly fat - Express

Read More...

A breast tumor might have thousands of mutations. Which are important? – Fred Hutch News Service

February 13th, 2020 12:45 pm

Beronja and Ying dont think their approach has solved every problem for one, mice are still not humans. Also, most breast cancer-causing mutations are acquired later in life, whereas their approach introduces potential cancer-causing mutations while mice are still embryos. However, breast tumors in their model take about the same length of time to develop as those that develop in models where mutations are introduced to adult mice, Beronja said.

Ying screened 520 breast cancer-associated mutations from the TCGA for their effects on tumor development. Most have been found in fewer than 5% of breast cancer patients, and most are in genes of unknown function. He tested them in the context of a known cancer-driving mutation in the gene PIK3CA, the most commonly mutated gene in breast cancer. This would tell him whether these rare mutations commonly found in cancer cells that also have altered PIK3CA are riding its coattails or acting as co-captains.

While many of the mutations had no effect, 17 accelerated tumor growth and development. Whats more, Ying found that several of them shifted the tumors from a less-aggressive luminal subtype to a HER2-positive subtype.

That's something that was previously unknown, Ying said.

Though PIK3CA mutations were thought to dictate a luminal type of breast tumor, mutations in this gene are found in all four breast cancer subtypes, suggesting that other mutations influence tumor type when paired with altered PIK3CA. Their new approach might provide a platform for researchers to understand how, Ying said.

He chose one mutation in a gene called Tsc22d1 to explore more deeply. Tsc22d1 is deleted in about 2% of patients whose mutations are logged in TCGA. This mutation was one of those that Ying had found to enhance PIK3CA-driven tumor development and shift tumors to a HER2-like molecular subtype. His experiments shed light on the function of Tsc22d1, showing that in its unmutated form it acts to suppress PIK3CA-driven tumor growth.

The approach has potential far beyond screening cancer mutations, the scientists said. When Ying was developing his approach, he used his barcodes to trace mammary tissue development and discover that each mouse mammary gland arises from about 120 progenitor cells.

This question that Zhe ended up addressing which is, how many early stem cells give rise to an adult tissue? that's not known for any tissue in a mouse system or a human system, Beronja said. Its my favorite part of the study.

Yings approach could be used to answer similar questions for other tissues, such as skin or the cells lining the mouth, or perhaps to investigate questions surrounding the loss of stem cells as we age, Beronja said. A deeper understanding of these processes could be the first step toward correcting problems in tissue development or slowing the aging process.

Ying hopes that the functional information gleaned from his approach could support precision oncology by identifying future treatment targets.

Such information could directly affect treatment strategy, he said. I think this is the most direct way of translating those results from large genomic projects [like TCGA] into treatment, or at least identifying potential targets.

He and Beronja aim to apply their new strategy to develop mouse models of breast cancer that currently dont exist. One they want to create is a model in which metastasis, or cancer spread, occurs spontaneously and is driven by patient-derived mutations. Another is a spontaneous model of the most aggressive type of breast cancer, triple-negative, or basal-like, which currently lacks any options for targeted treatment. (In contrast, targeted treatments are on the market to treat people with each of the other three types of breast cancer.)

Most cancer-associated mutations are found in genes of unknown function. Beronja thinks his and Yings approach could solve this knowledge gap.

If our little lab is capable to test 520 [mutations] and identify 17 new drivers of tumorgenicity [tumor growth] and fully validate one of them if we can do it, there's really no excuse for the unknown category among the mutations, he said.

This work was funded by the National Institutes of Health, the National Cancer Institute, a Safeway Early Career Award in Cancer Research, and a Thomsen Family Fellowship.

Visit link:
A breast tumor might have thousands of mutations. Which are important? - Fred Hutch News Service

Read More...

New Report Counters Claims on the Origin of Gastric Cancer – The Scientist

February 13th, 2020 12:45 pm

Chief cells lie at the base of the stomachs gastric glands, and in healthy individuals they are responsible for secreting enzymes required for digestion. Scientists have proposed that, in the face of injury or genetic mutations, these cells revert back to stem cellsor dedifferentiateand give rise to abnormal changes in tissue called metaplasia, a precancerous state.

This idea emerged more than a decade ago from the observation of a specific type of metaplasia in stomach tissue called spasmolytic polypeptide-expressing metaplasia (SPEM), which appeared to originate from chief cells. Over the years, the body of evidence supporting this hypothesis has grown. But some scientists still question whether chief cells truly give rise to the precursors of cancer.

Yoku Hayakawa, a professor of gastroenterology at the University of Tokyo in Japan, is one of the skeptics. He says there have been technical limitations with the previous work, such as the lack of specificity of chief cell markers, and the use of transgenic mouse models that required tamoxifen, a drug that can induce injury and inflammation, to activate the oncogenic Krasgene.

In a study published last week(February 4) in Gastroenterology, Hayakawa and his colleagues investigate some of these issuesand conclude that their findings tip the scales against the chief cell hypothesis.

To address some of the limitations of previous research, Hayakawa and his colleagues identified a new, more-specific chief cell maker that targets the estrogen receptor GPR30 and established a mouse model of gastric metaplasia that activates Kras within the stomach without tamoxifen. When they induced a cancer-causing mutation in the mice, they found that most of the GPR30-expressing chief cells died instead of reverting their identity to stem cells. The team reported similar results when they injured the stomach using drugs or Helicobacter pylori,a bacterium known to increase the risk for cancer.

These findings counter results from previous studies supporting the chief cell hypothesis, Hayakawa tells The Scientist.They think chief cells are dedifferentiated, but [they are] lost.

The team did find stem cells that gave rise to metaplasia in the spots where the chief cells had died. But based on lineage tracing experiments with their Kras-activatedmice, the authors conclude that these cells were not derived from chief cells, but had instead migrated from higher up in the gland. This observation is consistent with a long-standing idea that stem cells from elsewhere in the gland are responding to replenish the dead chief cells, Hayakawa tells The Scientist. The epithelium has to regenerate to maintain homeostasis. So, in this case, stem cells actually expand and try to give rise to chief cells, which are lost.

According to Hayakawa, although these findings dont rule out that chief cells may give rise to metaplasia in rare cases, they suggest that gastric stem cells from the upper part of the gland are the main source of metaplasia in the stomach. The data clearly suggests stem cells or progenitors give rise to metaplasia but chief cells do not, he says.

Jason Mills, whose lab at Washington University School of Medicine has published several studies supporting the hypothesis that dedifferentiated chief cells can give rise to metaplasia, is not convinced. A key limitation of this study, he says, is that the authors conclusions depend largely on the assertion that GRP30labels all chief cells and only chief cells, which he does not think has been adequately demonstrated. (He notes there are differences in GPR30expression patterns in some of the papers figures, indicating that chief cells arent consistently or uniformly labeled.)

Mills adds that the results from this study arent actually too far off from those obtained in his own work, which has also revealed a subset of chief cells that do not undergo metaplasia. However, while his lab demonstrated that there are other chief cells that do give rise to SPEM, Hayakawas team concludes that the cells that give rise to the metaplasia in their experiments must not be chief cells. If you focus on the positive rather than the negative [in their results], we probably would not be too far off in our conclusions about chief cell behavior, he says.

Linda Samuelson of the University of Michigan says that a tamoxifen-independent mouse model of gastric metaplasia is an important contribution to the field. However, she, too, disagrees that this study rules out the chief cell dedifferentiation hypothesis. Its likely that both hypothesesa precancerous state arising from either stem cells or dedifferentiated chief cellsare correct, Samuelson tells The Scientist.She adds that the differences in outcome likely depend on factors such as how metaplasia is induced and the method used to track the cellular changes.

Regardless of whether the chief cell hypothesis turns out to be true, the question of how SPEM gives rise to gastric cancer remains unanswered, Hayakawa says. James Goldenring, who studies gastric cancer at Vanderbilt University Medical Center and is among those who originally proposed that chief cell dedifferentiation can give rise to SPEM, agrees that this an open question. But hes not convinced that his hypothesis should be discarded. It took me at least 10 years to get people to actually even admit that SPEM existed. So its perhaps ironic that were now arguing over how its created, he says. I guess thats better than where it started out, right? Weve taken the discussion to a different level.

M. Hata et al., GPR30-expressing gastric chief cells do not dedifferentiate but are eliminated via PDK-dependent cell competition during development of metaplasia,Gastroenterology,doi:10.1053/j.gastro.2020.01.046, 2020.

Diana Kwon is a Berlin-based freelance journalist. Follow her on Twitter @DianaMKwon.

Excerpt from:
New Report Counters Claims on the Origin of Gastric Cancer - The Scientist

Read More...

Ethan Zohn on Survivor: 5 Fast Facts You Need to Know – Heavy.com

February 13th, 2020 12:45 pm

Ethan Zohn is one of the 20 returning contestants to the Survivor game for season 40 of the series and this is his third time on the show. He previously won Survivor: Africa, which was season three, making him the second-earliest returnee for Winners at War behind only Amber Brkich Mariano, who appeared on season two. But he is the earliest winner to return because Amber didnt win until season eight.

Zohn also played on Ambers winning season, All Stars, where he was the sixth person voted out.

Heres what you need to know about the Survivor champ.

Zohn was born and raised in Lexington, Massachusetts, the youngest of three boys (his older brothers are Lenard and Lee, according to the Grassroots Soccer website. Zohn played soccer hes a goalkeeper for Lexington High School and Vassar College, where he majored in biology and marine biology, before going on to play professionally for the Hawaii Tsunami and Cape Cod Crusaders in the U.S. and for the Highlanders FC in Zimbabwe. On the Zimbabwe team, one of Zohns teammates died of AIDS.

In 2008, Zohn used some of his Survivor winnings to found Grassroots Soccer, an organization that aims to educate and prevent HIV and AIDS. Grassroots Soccer sends professional African soccer players into classrooms to teach middle-schoolers about HIV, using a curriculum that combines soccer and academics.

We are really trying to create this generation of HIV-negative kids, said Zohn in a 2008 interview, adding, In Africa, soccer players are heroes. They are like role models, the gods of the community. We train local professional soccer players about HIV and AIDS, and they go into the schools and teach the youths about AIDS prevention.

The program has since expanded to the Dominican Republic and Guatemala.

In 2009, Zohn was diagnosed with a rare type of cancer called CD20-positive Hodgkins lymphoma and shortly thereafter he underwent chemotherapy and stem-cell transplants to fight the disease. He went into remission in April 2010, but the cancer returned in September 2011.

That time around, he had to remain in his New York City apartment at all times when he wasnt going to the doctor and eventually received two rounds of stem-cell transplants from his brother, which were finally successful in early 2013.

I am in remission. Today is a special day, Zohn told CBS News on March 1, 2013. One year ago today I received my brothers stem cells they wiped out my body and infused my brothers stem cells into my body. So if you take my DNA sample, its like my brother.

He added that it had been so hard to be so isolated from everyone.

I have been spending a lot of time with my family, which is very exciting, he said. Ive been in isolation for seven months. I couldnt really leave my apartment unless I was going to the doctor. I just got clearance, so Ive been traveling a little bit, visiting friends and family. I got to hug my nieces and nephews for the first time in a year.

Jenna Morasca won the sixth season of Survivor and it was afterward that she met Zohn. The two began dating in 2003 and were together for a decade. In the time they were together, they appeared on both Survivor: All-Stars and The Amazing Race.

On All-Stars, Morasca famously left the game after nine days because her mothers cancer diagnosis had taken a turn for the worse right before the show began filming. Her mother died a week after she returned home.

After her departure from that season, Morasca told the Pittsburgh Post-Gazette, [Ethans] a great guy, and hes really been there for me. You cant know him and not love him.

In 2011, the two of them appeared in a 20-minute horror short called The Watcher as part of an anthology called Drive-In Horrorshow, which you can watch on YouTube. Then in early 2013, they decided to call it quits.

It is with much consideration and a heavy heart that we are announcing that after 10 years of a loving relationship, the decision was made to move on without each other, the couple said in a joint statement at the time of their breakup. We will carry with us the memories of a relationship grounded in love, laughter, support and friendship. We have experienced some of lifes greatest joys and toughest challenges together, and our decision to be apart can never diminish that. We want to thank everyone for their support and we ask that our privacy be respected as we move forward.

A few years after ending things with Morasca, Zohn began dating New York City interior designer Lisa Heywood. He told People at the time, This is the reason I survived cancer twice to meet Lisa and start a beautiful and healthy new life together.

The two met in 2013 at a Clinton Global Initiative charity event and then two years later, Zohn asked her to marry him on the dock of their New Hampshire lake house, using the ring his late father had given his mother. The two got married in July 2016 in Vermont.

Before the ceremony, they told People that they looked forward to standing together and taking a quiet moment to look at all our family and friends that have supported us along the way. They also said theyre looking forward to getting chubby and growing old together, and the potential we have to make the world a better place by the virtue of being together as one.

Zohnthen predicted that all the happy and sad tears in my life will disappear in her presence.

Ethan Zohn Says Being On Season 40 Of Survivor Is An Absolute Miracle | SURVIVORSurvivor: Africa winner Ethan Zohn tells Sangita Patel that he was a little bit intimidated when he got the call to play on Survivor: Winners at War having had no experience with hidden immunity idols, blindsides and more. Plus, he reveals that hes seven years in remission since being diagnosed with blood cancer at the age of 35. Tune in to the premiere of Survivor: Winners at War on Wednesday, Feb. 12 at 8 p.m. ET/PT on Global. SUBSCRIBE to our channel: https://www.youtube.com/user/ETCanadaOfficial FOLLOW us here: http://www.etcanada.com Facebook: https://www.facebook.com/etcanada Twitter: http://www.twitter.com/etcanada Instagram: http://www.instagram.com/etcanada #Survivor #EthanZohn #SurvivorWinnersAtWar2020-01-15T16:00:06.000Z

In a pre-Winners at War interview with ET Canada, Zohn says he was intimidated to come back after so many years.

To put this in perspective, the last time I played the game was 16 years ago, that was Survivor: All-Stars and the season I won was Survivor: Africa, which was in 2001! This is before hidden immunity idols, clues, ways to get back in the game Ive never done any of that stuff, so as you can imagine, I was a little intimidated and nervous when I got the call to come back for season 40, says Zohn, though he adds that he feels ready to be here because he put in the training and the effort and [he feels] prepared for whats to come.

Zohnalso says that just getting here is an absolute miracle because of what he overcame when he was so sick with cancer.

I remember I was locked in my hospital room, getting my second stem-cell transplant, watching Heroes vs Villains, praying to myself that Id be alive long enough that Id be able to play again I just wanted to get healthy enough so I could come back and play Survivor. I knew there had to be an all-winners season coming at some point and I wanted to be part of that.

Survivor: Winners at War airs Wednesdays at 8 p.m. ET/PT on CBS.

READ NEXT: Meet the Survivor: Winners at War Cast

More here:
Ethan Zohn on Survivor: 5 Fast Facts You Need to Know - Heavy.com

Read More...

Meet The Super-Rich Spending 4,000 A Month On Their Health – Yahoo Style

February 13th, 2020 12:45 pm

From ELLE

Martha* looks expensive. Not freshly minted footballers wife expensive. Not bouncy-haired ladies who dont lunch expensive. But quietly expensive: skin that glimmers like the Cullinan Diamond; a body as smooth as Carrara marble. Just unmistakably well crafted. And so she should: the 34-year-old luxury retailer spends almost 4,000 a month thats how much it costs to be tweaked and perfected by the latest advances in health.

Theres the weekly three-minute cryotherapy sessions at 100 a pop. Then theres the 125 personal training workouts, of which she has four each week. Theres also the mandatory 150 monthly vitamin drip and at least one massage a fortnight (call it 160), as well as a personalised supplement plan that seems a bargain at 50 per week. Thats around 4,000, including the cryo, but not including facials and beauty things, of course, she says. Of course. And, to be fair, its working for her. With her plump, practically line-free face, and raven hair so shiny you could almost reapply your lipstick in front of it, she is a walking advertisement for the power of whacking a hefty monthly mortgage payment at your health.

Photo credit: Luca Cannonieri

But how much is good health really worth? Apparently, when youre part of the super-rich set, the answer is: a lot. When UBS investment bank surveyed its millionaires, nine out of ten agreed that health is more important than wealth with its highest earners willing to give up half of their fortune to guarantee an extra decade of good health. Because when you have everything money can buy, what you really want is the one thing it cant. Until now.

An entire industry has sprung up over the past decade, catering largely to the wealthiest 1%, but also to mere fiscal mortals, too, who aspire to perfect health in the way they once aspired to own a Birkin bag. Take last years two-day Goop conference, where doctors, scientists and health-mad celebrities took to the stage at Londons Re:Centre sanctuary. A one-day ticket set visitors back 1,000. But for a two-day, full-access pass with VIP workouts and a room at the shiny new Kimpton Fitzroy Hotel? Try 4,500.(According to Goop, all of these full-access tickets sold out.)

Or take the new offering from the exclusive Arts Club in London, which has teamed up with Lanserhof, the almost mythical Austrian health retreat that has been peddling longevity and luminosity for decades. Now, those members can pay 6,500 a year (non-members will have to cough up an extra 1,500) to have access to their on-site Lanserhof clinic. For that they can throw as much at their health and body as they like, with MRI scans, DNA tests, osteopathy sessions, shock wave therapy, acupuncture treatments... the list goes on. And on.

At the top end of the health scale, however, the sky is the limit. At RAAD fest, an annual conference held in the US attended by many of the worlds leading billionaires, a number of scientists and technologists parade the latest evolutions in healthcare. They are dystopian-sounding technologies, such as hyperbaric oxygen chambers that offer expediated healing, as well as stem cell IV infusions (yours for around 875 a pop).

Photo credit: Alessandro Zeno - Imaxtree

Story continues

What do they all have in common? A big price tag and the promise of immortality. After all, RAAD stands for The Revolution Against Ageing and Death, and is organised by the controversial Coalition for Radical Life Extension. Their mission: to help the super-rich dispose of their money before they hit their graves.But, ideally for them, not to hit their tombstones... ever.

Dr Sabine Donnai is the founder of private health service Viavi and creator of its Health Assessment and HealthStrategy, seen as the Aston Martin of health programmes. Donnai, previously the medical director at Nuffield Health Wellbeing, saw a gap in the market for an assessment that went beyond the norm. The market was there. Theyve worked hard, theyve made money and now they ask, I want to continue enjoying this, so what do I do?, she explains. They want the data. They want the control. They want to understand what their health looks like.

Her clientele is split into two groups. The first: the worried well, seeking preventive measures. They come to us to understand a thorough picture of their health and what they can do to improve it, says Donnai. For example, a hormone test might reveal underlying reasons for weight gain, or a toxin level result might expose risks to your immune system. The second, smaller group have been diagnosed with a problem, but want to solve it rather than treat it. The difference is important. Say they have cancer we arent oncologists or surgeons, but our role might be to identify how they could prevent it from returning. They dont want to be hassled by illness, says Donnai. But want to live a better life.

Viavis assessment can go as far as the client chooses. In a single day, you can have everything from a transvaginal scan and breast ultrasound to a urine hormone screen and toxic body burden test. When I ask one client, an international business owner in her forties, why she chose to invest in the test, she says, Its the best. Its hard to put a price on it... she trails off. Viavi, however, is happy to do so: the full Health Assessment and Health Strategy costs 15,000.

On the other side of the city, Workshop Gymnasium is doing for fitness what Viavi is doing for health: catering to the demands of the richest 1%. Hidden in Knightsbridge, beneath the Bvlgari Hotel, it looks more like a hedge fund managers apartment than a gym, with wooden floors, honeyed lighting and towers of glossy green apples beside fans of shiny magazines.

Its top-tier membership will set you back 13,000 a year. There are also add-ons, including supplements and physiotherapy, pushing some members spend past the 20,000 mark. Its where Martha splurges on her 125 an hour PT sessions with founder Lee Mullins, who reports increasing interest in his services from around the world. (Workshop has locations in China, Milan, Dubai and Bali.) They want a customised approach and come for the assessments we offer to tailor their programme, he says of his client base of CEOs, entertainment industry types and models.

They also get training on demand Workshop offers a 24/7 service, in a private setting if requested, with total discretion. Mullins is tight-lipped about his celebrity clients, save a handful of models, including brand ambassadors Amelia Windsor, Clara Paget and Eliza Cummings. Clients can even have a trainer travel with them on business trips or holidays for a fee of up to 2,000 per day.

There are options for those with slightly less disposable income. At BelleCell, a biohacking clinic next to The Ritz London, packages are available at varying levels. Set in a 500-year-old vault, comprising a series of spaceship-like pods, it serves to optimise cell performance and recovery and offer effective health solutions total wellbeing on a molecular level. Which, in English, means they claim to make you better, stronger and healthier. This includes full bio-analysis tests and cell-optimising treatments (oxygen pods, vitamin infusions, alien-esque capsules in which to exercise). The top package, a Genetic Test for Life, will set you back almost 3,000, but therapies start from 110 in order to be accessible to everyone, says founder Kasia Zajkowska, a former molecular bio-scientist. Well, maybe not exactly everyone...

Dropping up to 15,000 on a health test attracts a specific section of the super-wealthy, one thats already aware and selective about wellness, says Zajkowska. She claims theyre not doing it for vanity: Their choice to spend is for the most part not about aesthetics, but future proofing. For some, the investment in themselves does come with more of a beauty focus. Carrie, a 51-year-old property business company director, who lives in Cheshire, tells me that yes, she goes to the gym and takes supplements for health and longevity, but she wants to look better, too. She spends almost 10,000 a year on aesthetics alone (monthly facials, radio frequency and micro needling) money that is more than pocket-change to her. But shes willing to prioritise the spend for the results.

For many, even a single treatment at one of these clinics would be a luxury or an impossibility. Never mind a super-screening that costs more than some house deposits. But in England, with the NHS available to all, are they even necessary? Women are offered free cervical screening from the age of 25, free breast screening from 50 and a free NHS health check from 40. This extensive check looks for early signs of high blood pressure, diabetes, kidney disease, heart disease and dementia. And, according to former NHS GP Dr Juliet McGrattan, it could be the better option, even when you do have money to blow, due to the legitimacy of the tests.

Photo credit: Astrid Stawiarz

With any screening test, there is a possibility that a false positive (when something is detected that isnt actually a problem) or a false negative (when something is missed) may occur, she tells me. The NHS has meticulously evaluated its offering to try to ensure it has the lowest number of these results. Her worry is that private tests may not have been so thoroughly evaluated. She adds that private companies cant always offer care beyond the test, so you might be directed to your NHS GP anyway. In her opinion, theres no need to part with money.

As for Martha, her 4,000 monthly investment is about boosting energy, feeling better and staying strong, something us mere mortals can relate to as we weave a rather less extortionate version of wellness into our daily lives. But she admits, Appearances matter. I have to look the part and be seen to be taking part. It seems that consumption isnt always so inconspicuous after all.

*Name has been changed

You Might Also Like

Read more from the original source:
Meet The Super-Rich Spending 4,000 A Month On Their Health - Yahoo Style

Read More...

Meet The Super-Rich Spending 4000 A Month On Their Health – elle.com

February 13th, 2020 12:45 pm

Martha* looks expensive. Not freshly minted footballers wife expensive. Not bouncy-haired ladies who dont lunch expensive. But quietly expensive: skin that glimmers like the Cullinan Diamond; a body as smooth as Carrara marble. Just unmistakably well crafted. And so she should: the 34-year-old luxury retailer spends almost 4,000 a month thats how much it costs to be tweaked and perfected by the latest advances in health.

Theres the weekly three-minute cryotherapy sessions at 100 a pop. Then theres the 125 personal training workouts, of which she has four each week. Theres also the mandatory 150 monthly vitamin drip and at least one massage a fortnight (call it 160), as well as a personalised supplement plan that seems a bargain at 50 per week. Thats around 4,000, including the cryo, but not including facials and beauty things, of course, she says. Of course. And, to be fair, its working for her. With her plump, practically line-free face, and raven hair so shiny you could almost reapply your lipstick in front of it, she is a walking advertisement for the power of whacking a hefty monthly mortgage payment at your health.

But how much is good health really worth? Apparently, when youre part of the super-rich set, the answer is: a lot. When UBS investment bank surveyed its millionaires, nine out of ten agreed that health is more important than wealth with its highest earners willing to give up half of their fortune to guarantee an extra decade of good health. Because when you have everything money can buy, what you really want is the one thing it cant. Until now.

An entire industry has sprung up over the past decade, catering largely to the wealthiest 1%, but also to mere fiscal mortals, too, who aspire to perfect health in the way they once aspired to own a Birkin bag. Take last years two-day Goop conference, where doctors, scientists and health-mad celebrities took to the stage at Londons Re:Centre sanctuary. A one-day ticket set visitors back 1,000. But for a two-day, full-access pass with VIP workouts and a room at the shiny new Kimpton Fitzroy Hotel? Try 4,500.(According to Goop, all of these full-access tickets sold out.)

'They can throw as much at their health and body as they like, with MRI scans, DNA tests...'

Or take the new offering from the exclusive Arts Club in London, which has teamed up with Lanserhof, the almost mythical Austrian health retreat that has been peddling longevity and luminosity for decades. Now, those members can pay 6,500 a year (non-members will have to cough up an extra 1,500) to have access to their on-site Lanserhof clinic. For that they can throw as much at their health and body as they like, with MRI scans, DNA tests, osteopathy sessions, shock wave therapy, acupuncture treatments... the list goes on. And on.

At the top end of the health scale, however, the sky is the limit. At RAAD fest, an annual conference held in the US attended by many of the worlds leading billionaires, a number of scientists and technologists parade the latest evolutions in healthcare. They are dystopian-sounding technologies, such as hyperbaric oxygen chambers that offer expediated healing, as well as stem cell IV infusions (yours for around 875 a pop).

What do they all have in common? A big price tag and the promise of immortality. After all, RAAD stands for The Revolution Against Ageing and Death, and is organised by the controversial Coalition for Radical Life Extension. Their mission: to help the super-rich dispose of their money before they hit their graves.But, ideally for them, not to hit their tombstones... ever.

Dr Sabine Donnai is the founder of private health service Viavi and creator of its Health Assessment and HealthStrategy, seen as the Aston Martin of health programmes. Donnai, previously the medical director at Nuffield Health Wellbeing, saw a gap in the market for an assessment that went beyond the norm. The market was there. Theyve worked hard, theyve made money and now they ask, I want to continue enjoying this, so what do I do?, she explains. They want the data. They want the control. They want to understand what their health looks like.

'They dont want to be hassled by illness, but want to live a better life'

Her clientele is split into two groups. The first: the worried well, seeking preventive measures. They come to us to understand a thorough picture of their health and what they can do to improve it, says Donnai. For example, a hormone test might reveal underlying reasons for weight gain, or a toxin level result might expose risks to your immune system. The second, smaller group have been diagnosed with a problem, but want to solve it rather than treat it. The difference is important. Say they have cancer we arent oncologists or surgeons, but our role might be to identify how they could prevent it from returning. They dont want to be hassled by illness, says Donnai. But want to live a better life.

Viavis assessment can go as far as the client chooses. In a single day, you can have everything from a transvaginal scan and breast ultrasound to a urine hormone screen and toxic body burden test. When I ask one client, an international business owner in her forties, why she chose to invest in the test, she says, Its the best. Its hard to put a price on it... she trails off. Viavi, however, is happy to do so: the full Health Assessment and Health Strategy costs 15,000.

On the other side of the city, Workshop Gymnasium is doing for fitness what Viavi is doing for health: catering to the demands of the richest 1%. Hidden in Knightsbridge, beneath the Bvlgari Hotel, it looks more like a hedge fund managers apartment than a gym, with wooden floors, honeyed lighting and towers of glossy green apples beside fans of shiny magazines.

Its top-tier membership will set you back 13,000 a year. There are also add-ons, including supplements and physiotherapy, pushing some members spend past the 20,000 mark. Its where Martha splurges on her 125 an hour PT sessions with founder Lee Mullins, who reports increasing interest in his services from around the world. (Workshop has locations in China, Milan, Dubai and Bali.) They want a customised approach and come for the assessments we offer to tailor their programme, he says of his client base of CEOs, entertainment industry types and models.

They also get training on demand Workshop offers a 24/7 service, in a private setting if requested, with total discretion. Mullins is tight-lipped about his celebrity clients, save a handful of models, including brand ambassadors Amelia Windsor, Clara Paget and Eliza Cummings. Clients can even have a trainer travel with them on business trips or holidays for a fee of up to 2,000 per day.

There are options for those with slightly less disposable income. At BelleCell, a biohacking clinic next to The Ritz London, packages are available at varying levels. Set in a 500-year-old vault, comprising a series of spaceship-like pods, it serves to optimise cell performance and recovery and offer effective health solutions total wellbeing on a molecular level. Which, in English, means they claim to make you better, stronger and healthier. This includes full bio-analysis tests and cell-optimising treatments (oxygen pods, vitamin infusions, alien-esque capsules in which to exercise). The top package, a Genetic Test for Life, will set you back almost 3,000, but therapies start from 110 in order to be accessible to everyone, says founder Kasia Zajkowska, a former molecular bio-scientist. Well, maybe not exactly everyone...

'She spends almost 10,000 a year on aesthetics alone'

Dropping up to 15,000 on a health test attracts a specific section of the super-wealthy, one thats already aware and selective about wellness, says Zajkowska. She claims theyre not doing it for vanity: Their choice to spend is for the most part not about aesthetics, but future proofing. For some, the investment in themselves does come with more of a beauty focus. Carrie, a 51-year-old property business company director, who lives in Cheshire, tells me that yes, she goes to the gym and takes supplements for health and longevity, but she wants to look better, too. She spends almost 10,000 a year on aesthetics alone (monthly facials, radio frequency and micro needling) money that is more than pocket-change to her. But shes willing to prioritise the spend for the results.

For many, even a single treatment at one of these clinics would be a luxury or an impossibility. Never mind a super-screening that costs more than some house deposits. But in England, with the NHS available to all, are they even necessary? Women are offered free cervical screening from the age of 25, free breast screening from 50 and a free NHS health check from 40. This extensive check looks for early signs of high blood pressure, diabetes, kidney disease, heart disease and dementia. And, according to former NHS GP Dr Juliet McGrattan, it could be the better option, even when you do have money to blow, due to the legitimacy of the tests.

With any screening test, there is a possibility that a false positive (when something is detected that isnt actually a problem) or a false negative (when something is missed) may occur, she tells me. The NHS has meticulously evaluated its offering to try to ensure it has the lowest number of these results. Her worry is that private tests may not have been so thoroughly evaluated. She adds that private companies cant always offer care beyond the test, so you might be directed to your NHS GP anyway. In her opinion, theres no need to part with money.

As for Martha, her 4,000 monthly investment is about boosting energy, feeling better and staying strong, something us mere mortals can relate to as we weave a rather less extortionate version of wellness into our daily lives. But she admits, Appearances matter. I have to look the part and be seen to be taking part. It seems that consumption isnt always so inconspicuous after all.

*Name has been changed

More here:
Meet The Super-Rich Spending 4000 A Month On Their Health - elle.com

Read More...

Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in P | DMSO – Dove Medical Press

February 12th, 2020 11:49 pm

Qin Yang, Yingxiao Zhang, Qinglian Zeng, Chan Yang, Jiale Shi, Chunlin Zhang, Xia Ni, Zhipeng Du, Ziwei Tang, Jinbo Hu, Xuemei Li, Jiahui Cai, Qifu Li, Qingfeng Cheng

Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Peoples Republic of China

Correspondence: Qingfeng ChengThe First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400042, Peoples Republic of ChinaTel +86-23-89011510Fax +86-23-890115540Email cqf19760516@163.com

Purpose: The present study was designed to determine the relationships between sarcopenia and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and diabetic foot disease (DFD) respectively.Patients and Methods: A total of 1104 patients with T2DM and 257 patients with DFD were included in the study, which was designed as a cross-sectional study. Body composition was assessed using dual-energy X-ray-absorptiometry (DXA). The diagnosis of sarcopenia was based on the Baumgartner criteria. DPN was assessed by Neuropathy symptom score (NSS) and Neuropathy disability score (NDS), and the severity of neuropathy was divided into non-neuropathy symptom (NS), Mild NS, Moderate NS and Severe NS according to NSS. Logistic regression analyses were carried out to determine the relations of sarcopenia and DPN in patients with T2DM and NSS in patients with DFD, respectively.Results: The prevalence of DPN was 80.0% in T2DM patients with sarcopenia and 70.3% in non-sarcopenia patients (P=0.007). Logistic regression analyses showed DPN was one of the independent risk factors for sarcopenia in T2DM patients (OR 1.564 [95% CI: 1.004, 2.435], P=0.048). The prevalence of DPN had no statistical significance in DFD patients with or without sarcopenia. However, the NSS of DFD patients with sarcopenia was higher than that of non-sarcopenia patients. In the multivariate logistic regression analysis, NSS was determined to be associated with sarcopenia in DFD patients (OR 1.387[95% CI: 1.074, 1.789], P=0.012). The appendicular lean mass (ALM) of DFD patients without NS was higher than patients with mild, moderate and severe NS (20.71 2.73 vs 16.57 3.62 vs 17.99 3.54 vs 17.23 3.29 Kg, P=0.028).Conclusion: DPN is an independent risk factor for sarcopenia in patients with T2DM and NSS is also independently correlated with sarcopenia in patients with DFD, with the latter being more obvious with the aggravation of neurological symptoms in DFD patients.

Keywords: type 2 diabetes mellitus, diabetic peripheral neuropathy, diabetic foot disease, sarcopenia, correlation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in P | DMSO - Dove Medical Press

Read More...

This methodology reduces the danger of diabetes neuropathy in diabetes – Sahiwal Tv

February 12th, 2020 11:49 pm

Diabetic Neuropathy: High sugar ranges in blood can result in many ailments. One of its severe results is nerve injury ( Nerve injury ) is. In medical phrases its known as diabetic neuropathy ( Diabetic Neuropathy ) is known as. Diabetic neuropathy strikes the nerves of your toes and legs.

->But it might probably additionally have an effect on the fingers and arms. You might really feel ache and numbness. Sometimes, a tingling in your toes and toes can be an indication of this situation. It can have an effect on your digestive system, blood vessels, urinary tract in addition to your coronary heart. Therefore, it turns into essential to protect in opposition to it in time.

To keep away from nerve injury its essential to preserve blood sugar ranges beneath management. If its ignored for too lengthy, it might probably trigger incapacity. In very extreme circumstances, it is usually prone to trigger amputation of the limbs. The most harmful factor is that you could be not even know that youre experiencing nerve injury till its too late. This is as a result of the signs can generally be deceptive. Let us know how you can stop such sort of nerve injury in diabetes

Control your blood sugar stageControlling blood sugar ranges is the primary rule to forestall diabetic neuropathy. Keep your blood sugar ranges inside regular limits. If it fluctuates, discuss to your physician. He can change your medication. But, in your half, you must always monitor your blood sugar stage. You can simply do that at residence with a blood sugar meter. Also you should definitely go for the A1C take a look at each six months.

Take care of your toesYour toes are essential. It is essential to care for them. If nerve injury has already occurred, then you could be alert for any harm. This is as a result of you arent prone to really feel ache, your harm might trigger issues. Cut your nails commonly and pat your toes. Use lotion and apply it between your toes as effectively. Wash your toes with heat water and cleaning soap. Dry them effectively. Talk to your physician if you could put on any particular footwear for diabetic neuropathy. Even if it isnt obligatory, all the time put on comfy footwear.

Exercise safelyTalk about exercising in case of diabetes, then observe some guidelines. If you might be jogging or working, put on good high quality trainers. Some actions will not be good for you. Seek the recommendation of a educated skilled earlier than beginning any new train.

Read more:
This methodology reduces the danger of diabetes neuropathy in diabetes - Sahiwal Tv

Read More...

Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential…

February 12th, 2020 11:49 pm

DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (KLFE) (Kannalife or the Company), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Healths (NIH) National Institute on Drug Abuse (NIDA). The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple University (LKSOM) to assess KLS-13019, the Companys patented cannabidiol (CBD)-like molecule as a potential treatment of neuropathic pain and drug dependence.

The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

The animal model portion of the study was conducted by Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM. Dr. Ward had independently begun the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.

Im very excited about the results we have obtained with KLS-13019 to date. In our model, KLS-13019 is at least as effective as CBD to prevent neuropathic pain; however, KLS-13019 is also effective to reverse neuropathic pain as a consequence of cancer chemotherapy, whereas CBD was not effective under our test conditions. We will continue to explore the possibility that KLS-13019 could be even safer and more effective than CBD, stated Dr. Ward.

Kannalife performed pharmacology studies on the mechanism of action of KLS-13019 and its effects on the sodium-calcium exchanger (mNCX-1), an important regulator of mitochondrial function. Results of the studies performed by Douglas Brenneman, PhD, for Kannalife, have been published in the Journal of Molecular Neuroscience in a paper titled, Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.

For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells, stated Dr. Brenneman.

The completed study could lead to a Phase 2 grant and further advances Kannalifes belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2

The global market for neuropathic pain was valued at more than $5 billion in 2015, and in 2016, CIPN accounted for more than 42 percent of market revenue. Its estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 billion.3-4

The global opioids drug market was valued at $22.85 billion in 2017 and is expected to reach $32.6 billion by 2026, at a CAGR of 4.54% during a forecast period. Opioids are mainly used in cancer pain management and end-stage diseases in which painkilling care is required. The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drugs market. Extensive misuse of opioids, the growing incidence of death related to opioid overdose, and the rising number of lawsuits against opioid manufacturers are hindering the growth of the market. 5

A recently released animated video from Kannalife describes a Mechanism of Action (MOA) for KLS-13019. This video can be accessed on the Companys website at http://www.kannalife.com and via Vimeo at https://vimeo.com/371214213.

Research reported in this press release was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the amount of $299,916 under award number 1R41DA044898-01.

Story continues

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Temple HealthTemple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHSs physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

About KLS-13019KLS-13019 is Kannalifes leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Companys family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References

CONTACT:

Public Relations:

Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Mike Mulvihill, Senior Counsel of PadillaP: 804-334-2292E: mike.mulvihill@padillaco.com

Investor Relations:Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

See the rest here:
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential...

Read More...

Suffering From Diabetic Neuropathy? Beware of These Complications – India.com

February 12th, 2020 11:49 pm

Diabetic neuropathy is a complication that occurs due to prolonged excessive blood sugar level. It basically damages the nerves present in legs and hands. Depending on the nerves, diabetic neuropathy has affected, you feel the symptom ranging from pain and numbness in legs to digestive problems, and cardiovascular issues.

If you are suffering from diabetes and is not able to control the blood sugar level, the walls of your blood vessels may become weak and get damaged. Apart from diabetes, a combination of factors including smoking, drinking alcohol, genetics, and inflammation in nerves can cause nerve damage. In case of non-availability of timely treatment, the condition may aggravate and lead to various complications. Here, we tell you about them.

Also known as a neuropathic joint, Charcot joint is a progressive joint disorder that causes discomforting pain sensation. It causes joints to deteriorate that shows symptoms including swelling in joints, instability, and joint deformity.

If diabetic neuropathy damages the nerves controlling your bladder, you wont be able to empty it completely. This can lead to the accumulation of bacteria in the bladder and kidneys. This is what is called urinary tract infection. This can make you disable to control the muscles that release urine and feel urination. This can further lead to leakage and unwanted embarrassment.

In case diabetic neuropathy leads to the damage of the nerves controlling the functions of your digestive tract, you will experience constipation, diarrhoea or both. Nerve damage associated with diabetes has been found to cause a condition called gastroparesis in which your stomach either empties too fast or not at all. This can lead to an excessive increase in blood sugar level.

Nerve damage has been found to affect the functions of your sweat gland and thus makes it problematic to control body temperature. If you have autonomic neuropathy, you will experience too much sweating. Notably, too little or no sweating can be debilitating.

Continue reading here:
Suffering From Diabetic Neuropathy? Beware of These Complications - India.com

Read More...

Flex Wheeler Battles Through Nerve Damage, Hits the Gym to Train Back – generationiron.com

February 12th, 2020 11:49 pm

Flex Wheeler has gone through a considerable amount over the past several months. It appears that his leg amputation was only one of the hardships that the bodybuilding legend has been going through physically. Now it appears that Flex Wheeler has been afflicted with another ailment.

The veteran bodybuilder has apparently been dealing with neuropathy. But rather than let this nerve damage diagnosis get him down, Flex Wheeler is once again showing the heart and resolve of a champion.

If a leg amputation couldnt keep Flex Wheeler out of the gym then you can bet a little nerve damage isnt going to stop the legend. Here he is hitting the gym to work back like a true savage.

From what everything Flex Wheeler has been through, it appears that nothing can hold this IFBB legend back.

For more news and updates, follow Generation Iron on Facebook, Twitter, and Instagram.

Managing Editor at Generation Iron, Jonathan Salmon is a writer, martial arts instructor, and geek culture enthusiast. Check out his Instagram, Twitter, Facebook, and Sound Cloud for in-depth MMA analysis.

Header image courtesy of Instagram

View post:
Flex Wheeler Battles Through Nerve Damage, Hits the Gym to Train Back - generationiron.com

Read More...

In-Vitro Toxicology/Toxicity Testing Market Trends, 2019-2024 – Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods -…

February 12th, 2020 11:48 pm

Dublin, Feb. 12, 2020 (GLOBE NEWSWIRE) -- The "In-Vitro Toxicology/Toxicity Testing Market by Product & Services, Toxicity Endpoint & Test (Carcinogenicity, Dermal Toxicity), Technology (Cell-based, HTS), Method (Cellular Assays), Industry (Pharmaceutical, Cosmetics), Region-Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The In-Vitro Toxicology Testing Market is Expected to Reach USD 12.7 Billion by 2024 from an Estimated USD 8.1 Billion in 2019, at a CAGR of 9.3%.

The opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth factors for this industry.

The increasing focus of the pharmaceutical and cosmetics industries on using in-vitro methods for product testing along with the improvement in silico methods for predictive toxicology studies are expected to offer significant growth opportunities for players in this market. However, the dearth of skilled professionals is a substantial market challenge.

The software segment is expected to grow at the highest rate during the forecast period.

Based on the product & service, the in-vitro toxicology testing market is segmented into consumables, assays, equipment, software, and services. The software segment is projected to witness the highest growth in the in-vitro toxicology testing market during the forecast period.

Growth in this segment is driven mostly by the rising number of new technologies to develop in-vitro signatures and computational models capable of predicting in vivo responses. Also, the increasing use of the latest software in the industry and the academia to predict toxicity by comparing the data of new substances with other structurally or biologically similar compounds, are expected to drive the growth of this segment.

The ADME segment is expected to account for the largest market share in 2018.

Based on toxicity endpoints & tests undertaken across all industries, the in-vitro toxicity testing market is segmented into ADME; skin irritation, corrosion, and sensitization; genotoxicity; cytotoxicity; ocular toxicity; organ toxicity; phototoxicity; dermal toxicity; and other endpoints & tests. The ADME segment accounted for the largest share of the in-vitro toxicity testing market in 2018. This can be attributed to the high adoption during the drug development process with the advantage of producing highly reproducible & accurate data.

Toxicogenomics is expected to grow at the highest rate during the forecast period.

The toxicogenomics segment is expected to grow at the highest CAGR during the forecast period, primarily due to the technological advancements taking place in the field of proteomics and genomics. Also, the improvements in proteomic technologies are enhancing the study of gene & protein activity during toxicity analysis. Technological advancements taking place in the field of proteomics and genomics will further drive the growth of this segment in the coming years.

Europe is expected to hold the largest share for players operating in the in-vitro toxicology testing market.

Europe accounted for the largest share of the in-vitro toxicology testing market in 2018. Factors such as high adoption of in-vitro toxicology testing assays and services in the cosmetics and chemical industries after the ban on animal testing in the region are among the few factors expected to contribute to the growth of this market.

Story continues

Market Dynamics

Market Drivers

Opposition to Animal Testing

Technological Advancements

R&D Toward Early Stage Toxicity Detection

Market Restraints

Reluctance of Regulatory Authorities to Consider Alternative Methods for Proving Safety and Efficacy

Failure to Establish the Intricacies of in Vivo Conditions, In Vitro

Lack of In Vitro Models to Study Complex Endpoints

Market Opportunities

Market Challenges

Company Profiles

Bio-Rad Laboratories, Inc.

Bioivt

Catalent, Inc.

Charles River Laboratories International, Inc.

Covance, Inc.

Creative Bioarray

Creative Biolabs

Cyprotex PLC

Eurofins Scientific SE

GE Healthcare

Gentronix Limited

GVK Biosciences Private Limited

Insphero

MB Research Laboratories

Merck KGaA

Promega Corporation

Qiagen N.V.

SGS S.A.

Shanghai Medicilon Inc.

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gea7u2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

More here:
In-Vitro Toxicology/Toxicity Testing Market Trends, 2019-2024 - Increasing Focus on Drug Discovery and Personalized Medicine Using In Vitro Methods -...

Read More...

Growing Biomedical Research and Focus on Personalized Medicine to Aid Cell Isolation Market available in the latest report – WhaTech

February 12th, 2020 11:48 pm

Global cell isolation market is expected to attain a CAGR of 18.8% during the forecast period.

The global cell isolation market accounted for $4.6 billion revenue in 2017, and it is expected to attain a CAGR of 18.8% during the forecast period (20182023). The demand for cell isolation products and services is increasing due to the rise in requirement for biopharmaceuticals, growing research activities in personalized medicine, and increasing government funding for research.

Cell isolation is the separation of one or multiple types of cells from a heterogenous cell population.

It has become an integral step in biological research, and routine diagnosis and treatment of certain diseases. Some cell types, such as blood cells, naturally exist in a separated form and thus can be isolated by employing centrifugation, whereas some others exist as solid tissues that require specific techniques to isolate the individual cell type.

The global cell isolation market is witnessing growth owing to the rising demand for biopharmaceutical products derived from natural sources, such as plants, animals, and humans, that are easier to manufacture than conventional pharmaceuticals.

Report at:www.psmarketresearch.com/market-ort-sample

The prevalence of neurological diseases, such as Parkinsons disease, amyotrophic lateral sclerosis, spinal cord injury, and autoimmune conditions, namely type 1 diabetes, multiple sclerosis, and Crohns disease is rising. This, coupled with the increasing awareness about these diseases, is impelling the governments of many countries to invest in biomedical research and related technology, thus giving a boost to growth of the cell isolation market and biopharmaceutical production as well.

People in developed countries are shifting toward personalized medicine, owing to their awareness and means to afford personalized treatment, as they can now avail of several reimbursement schemes. The advent of new technologies, such as genetic mapping via next-generation sequencing, which helps in identifying the gene responsible for a specific disease, is boosting the personalized medicine domain.

This growth in the personalized medicine domain is impacting the cell isolation market positively.

GLOBAL CELL ISOLATION MARKET SEGMENTATION

Market Segmentation by Product

Report: http://www.psmarketresearch.com/send-enion-market

Market Segmentation by Cell Type

Market Segmentation by Technique

Market Segmentation by Application

Market Segmentation by End User

This email address is being protected from spambots. You need JavaScript enabled to view it.

Continue reading here:
Growing Biomedical Research and Focus on Personalized Medicine to Aid Cell Isolation Market available in the latest report - WhaTech

Read More...

A team of scientists examined more than 2600 cancer genomes. Here’s what they found. – The Daily Briefing

February 12th, 2020 11:48 pm

A team of international clinicians and scientists on Wednesday published findings from a comprehensive review of more than 2,600 cancer genomes, which observers say could further pave the way for clinicians to prescribe precise treatments to cancer patients based on their genes.

The team, who published their findings in 23 papers in Nature and its affiliated journals, completed the research through a joint project of the International Cancer Genome Consortium (ICGC) and U.S.-funded Cancer Genome Atlas (TCGA) called the Pan-Cancer Analysis of Whole Genomes Project (PCAWG). The project involved more than 1,300 clinicians and scientists, including members of Harvard and the Broad Institute of MIT, from across 37 countries.

Whereas researchers in the past had only looked at 1% of the cancer genome that specifically codes for proteins, called the exome, this project analyzed the entire cancer genome. To understand this remaining 99%, a team of 16 working groups analyzed more than 2,600 whole genomes from 38 different tumor types using the field's largest publicly available whole-genome dataset. The project took six years.

The researchers were able to gain a more nuanced understanding of "driver mutations," or mutations that play a major role in driving cancer progression. While previous studies of the cancer exome had also shown common driver mutations, this study allowed the researchers to find more mutations in non-coding areas which have an impact on cancer progression. On average, the researchers found each type of cancer had four or five driver mutations. As a result of the research, only 5% of cancer tumors now have unknown genetic drivers.

These newly discovered driver mutations could potentially be new targets for new drugs and allow for more personalized care for cancer patients. Clinicians have long been frustrated that two patients with identical tumors can respond to the same treatments in different ways. This study moves the field closer to providing oncologists with a list of cancer-causing mutations that they can use to personalize treatment.

In addition, the researchers discovered a new way to "carbon date" cancer. The method allows researchers to identify old mutations involved in forming cancers and determine the relative timing between them. Using this technique, they found nearly 20% of mutations occurred years, or even decades, before the cancer was found. Fifty percent of these early mutations occurred in the same nine genes.

Gad Getz, a co-senior author of three of the papers and the director of bioinformatics at the Massachusetts General Hospital's Cancer Center and a professor of pathology at Harvard Medical School, said, "This large international effort shows the breadth of the types of research and new biological insight that are possible using whole cancer genome data."

Observers also noted that the findings could lead to better diagnostics and prevent cancer. "It's certainly true that this kind of sequencing will not mean that all cancers are cured," said Peter Campbell of the Wellcome Sander Institute, a PCAWG member. "But it points us to where we should be thinking about developing drugs for preventing resistance or treating it once it arises" (Drage O'Reilly, Axios, 2/6; McPherson, Harvard Gazette, 2/5; Kaiser, Science, 2/5).

Read the original:
A team of scientists examined more than 2600 cancer genomes. Here's what they found. - The Daily Briefing

Read More...

Personalized Medicine Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 – Instant Tech News

February 12th, 2020 11:48 pm

New Jersey, United States, The report titled, Personalized Medicine Market Size and Forecast 2026 in Verified Market Research offers its latest report on the global Personalized Medicine market that includes comprehensive analysis on a range of subjects like competition, segmentation, regional expansion, and market dynamics. The report sheds light on future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Personalized Medicine market. Get access to crucial market information. Market players can use the report back to peep into the longer term of the worldwide Personalized Medicine market and convey important changes to their operating style and marketing tactics to realize sustained growth.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=ITN&utm_medium=002

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Personalized Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Personalized Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Personalized Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Personalized Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Personalized Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=ITN&utm_medium=002

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=ITN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis, Personalized Medicine Market Trends, Personalized Medicine Market

Read more:
Personalized Medicine Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 - Instant Tech News

Read More...

Precision Medicine is Focus of Genedata, Crohn’s Foundation Project – IBD News Today

February 12th, 2020 11:48 pm

Genedata and the Crohns & Colitis Foundation completed a project aimed at advancing precision care for Crohns disease patients.Genedata, a biopharmaceutical research and development software company, worked with foundation investigators and clinicians to integrate and study multi-omic and clinical data culled from patients with Crohns, which, along with ulcerative colitis, is among the most common forms of inflammatory bowel disease (IBD).The data will be used to identify the biomarkers that can be the most useful in evaluating, within five years of IBD diagnosis, a person's risk of developing disease complications that require surgery.Crohns disease is a chronic, often debilitating disease, for which there is currently no cure, Andres Hurtado-Lorenzo, PhD, the foundations senior director of translational research, said in a press release. Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest.""There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course," he said.The foundation sought help with leveraging abundant clinical and molecular data. Multi-omics is an approach in which multiple datasets (such as genes or protein profiles) are combined and analyzed for new associations.Genedata used its precision medicine software platform, Genedata Profiler, to provide data analysis that could advance biomarker research efforts. Biomarkers are useful in predicting disease trajectory, which is crucial to personalized treatment plan development.We decided to im

Read the rest here:
Precision Medicine is Focus of Genedata, Crohn's Foundation Project - IBD News Today

Read More...

Study Shows That Caris Life Sciences’ ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer…

February 12th, 2020 11:48 pm

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery

IRVING, Texas, Feb. 12, 2020 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research,illustrating that use of the Company's proprietary ADAPT Biotargeting System can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate (LNCaP).

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

The paper, "ADAPT identifies an ESCRT complex composition that discriminates VCaP from LNCaP prostate cancer cell exosomes," also demonstrates that the ADAPT platform can be a powerful method that allows for the enrichment of polyligands that can distinguish even between different subpopulations of the same disease.

The results show that the ADAPT Biotargeting System has the resolution and sensitivity to discover differences in protein complexes using exosomes secreted by cancer cells from the same tumor type.

"The results of this research are highly significant in that they show that the ADAPT system can be deployed against multiple cancer types in various biological matrices and offers broad potential applications in biomarker discovery," said David Spetzler, M.S., Ph.D., M.B.A., President and Chief Scientific Officer of Caris Life Sciences, and an author of the study. "Further, we were able to show that in prostate cancer, ADAPT not only discriminated between cancer types but between subtypes of a specific lineage. We anticipate that this could potentially help inform treatment decisions based on the patient's specific molecular profile in prostate cancer and across a range of tumor types."

"The differences in the composition of the Endosomal Sorting Complex Required For Transport (ESCRT) pathway and associated complexes between exosomes derived from VCaP and LNCaP cells could point to them as novel biomarkers for these different prostate cancers," said Michael Famulok, Ph.D., University of Bonn (Germany), Life & Medical Sciences Institute (LIMES), Max Planck Fellow and co-author of the study. "We look forward to further investigating this potential and how the ADAPT system can be used to gain a greater understanding of the molecular composition of cells across tumor types."

The ADAPT Biotargeting System is Caris' proprietary unbiased profiling platform that uses a broad library of synthetically-manufactured molecules (aptamers) that bind to a wide range of biological targets and characterize complex biological systems in their native state, enabling them to profile biological samples at a systems-wide scale.

Thepaperwaspublishedonline on January 28 inNucleic Acids Research,andisavailableonlinehere and DOI:https://doi.org/10.1093/nar/gkaa034.

About Caris Life Sciences

Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.

Story continues

Caris is also advancing precision medicine with Next Generation Profiling that combines its innovative service offerings, Caris Molecular Intelligence and ADAPT Biotargeting System, with its proprietary artificial intelligence analytics engine, DEAN, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.

Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.

Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician's care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris' highest quality industry leading large-scale molecular profiling services with Pharmatech's on-demand site activation and patient enrollment system.

Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visitwww.CarisLifeSciences.comor follow us on Twitter (@CarisLS).

Media Contact:Lindsey BailysGCI Healthlindsey.bailys@gcihealth.com +1-212-798-9884

View original content to download multimedia:http://www.prnewswire.com/news-releases/study-shows-that-caris-life-sciences-adapt-biotargeting-system-has-discovered-protein-expression-pattern-differences-between-two-prostate-cancer-patient-subpopulations-301002804.html

SOURCE Caris Life Sciences

Read the rest here:
Study Shows That Caris Life Sciences' ADAPT Biotargeting System Has Discovered Protein Expression Pattern Differences Between Two Prostate Cancer...

Read More...

Brooks Bell: ‘Groundbreaking blood test determined there is 95% chance my cancer is gone and won’t return’ – WRAL Tech Wire

February 12th, 2020 11:48 pm

Editors note:Brooks Bell is the founder and CEO of her eponymous brand consulting firm.

RALEIGH A year ago, I was diagnosed with stage 3 colon cancer. Its been a tough year: 6 months of surgery and chemotherapy, followed by intense health recovery. I have made dramatic changes to my diet, fitness routine, and stress. This month, I received the news Ive been fantasizing about all year: Im cancer-free. A groundbreaking blood test determined that there is not a single molecule of my tumor cells currently in my blood. That, combined with a clear CT scan, means that there is a 95% chance that my cancer is gone and wont return. I am overjoyed.

When I received the news, Jes and I were just waking up in the Dominican Republic after celebrating our 21st anniversary together. I burst into tears of joy, and felt the burden of uncertainty lifting off my chest. It was a surreal moment. Id gotten accustomed to clawing back my health, questioning feelings of wellbeing.It was easy to imagine being one of the unlucky ones who has the cancer come back and spread (after all, I was already unlucky enough to get cancer in the first place).

This is what makes cancer so hard for many: even when youre done with your treatment, it takes years to fully relax again because up until now our existing technology has prevented us from knowing if the treatment was truly successful.

Not anymore.

The molecular test that I took is a cutting-edge technology calledNatera. It gives cancer patients personalized testing that involves doing ultra-deep DNA sequencing on your tumor cells, and then matching those to your blood to see if they are still floating around in your body.

It just got FDA breakthrough status in May, and I was the first patient at Duke Cancer Center to receive it.

I believe this test may be part of a paradigm shift in the cancer industry. Its a perfect example of the promise of personalized medicine and machine learning. It is going to give patients clear insight on whether their treatment has been successful, and maybe even if chemotherapy is even necessary for them. Its pretty incredible, and I am so lucky to be able to benefit from it. Go Duke! Go Natera!

Brooks Bells new cause. (Brooks Bell image)

I will be celebrating toasting my health and the50 Colonoscopies Under 50 honorees with my friends and supporters at The Colonoscopy Gala on Feb. 28 at CAM Raleigh. I would love for you to be there with me (especially if you are based in NC).

This may be the first ever Colonoscopy Gala in the history of time. A colonoscopy is the most effective way to protect yourself from colon cancer, and it deserves a night to be celebrated.

Itll be an evening to remember. We will have asuper talented chefdoing a five-course seated dinner for us, and you may be able to even get bring home a one-of-a-kind street-artist designedTushy Ottoman..

And of course, its for a good cause; all proceeds go to the astonishingly underfunded Colorectal Cancer Alliance.

Tickets are $175 each, and are available until Feb. 17. RSVP or donate here.

Brooks Bell: I finished my chemo treatment, feeling fantastic

Six months after cancer diagnosis, Brooks Bell appoints successor to run her brand consulting firm

Go here to see the original:
Brooks Bell: 'Groundbreaking blood test determined there is 95% chance my cancer is gone and won't return' - WRAL Tech Wire

Read More...

Page 706«..1020..705706707708..720730..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick